162 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 32892505 | Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays. | 2021 Feb | 1 |
2 | 33034200 | Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates. | 2020 Jan-Dec | 1 |
3 | 30086574 | Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery. | 2018 Sep | 1 |
4 | 30194803 | Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology. | 2018 Nov | 2 |
5 | 26377606 | The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin. | 2016 Jun 5 | 1 |
6 | 26607136 | Role of exosite binding modulators in the inhibition of Fxa by TFPI. | 2016 Mar | 3 |
7 | 27566697 | Modulation of factors involved in placental haemostasis and angiogenesis by low-molecular-weight-heparins. | 2016 Nov | 1 |
8 | 25525049 | Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model. | 2015 Apr | 2 |
9 | 24266905 | Early heparin administration attenuates tissue factor-mediated thrombin generation during simulated cardiopulmonary bypass. | 2014 Jan | 7 |
10 | 23320987 | TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. | 2013 Jan 15 | 1 |
11 | 22302552 | Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients. | 2012 Feb 14 | 4 |
12 | 19959490 | Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates. | 2010 Feb | 1 |
13 | 20592020 | C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. | 2010 Sep 3 | 2 |
14 | 20880110 | Novel interactions between UFH and TFPI in children. | 2010 Nov | 7 |
15 | 21162606 | Bemiparin: pharmacological profile. | 2010 Dec 14 | 1 |
16 | 19218095 | Regulation of thrombin generation by TFPI in plasma without and with heparin. | 2009 Mar | 2 |
17 | 19285275 | Heparanase coagulation and cancer progression. | 2009 Mar | 2 |
18 | 19731406 | Tissue factor pathway inhibitor release and depletion by sulodexide in humans. | 2009 | 2 |
19 | 19736157 | A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. | 2009 Aug | 2 |
20 | 18160611 | Further insight into the heparin-releasable and glycosylphosphatidylinositol-lipid--anchored forms of tissue factor pathway inhibitor. | 2008 Jul | 9 |
21 | 18261960 | Expression of tissue factor pathway inhibitor by endothelial cells and platelets. | 2008 Feb | 1 |
22 | 18645924 | Heparanase, tissue factor, and cancer. | 2008 Mar | 1 |
23 | 18716314 | Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin. | 2008 Oct | 2 |
24 | 16824584 | Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. | 2007 | 6 |
25 | 16919311 | Relative quantification of glycosaminoglycan-induced upregulation of TFPI-mRNA expression in vitro. | 2007 | 5 |
26 | 17376263 | [Highlighting the potential of heparin in the treatment of sepsis in view of failure of KyberSept and OPTIMIST projects]. | 2007 Mar | 2 |
27 | 16461305 | Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. | 2006 Feb | 1 |
28 | 16520718 | Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. | 2006 Mar | 4 |
29 | 16689752 | Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass. | 2006 May | 9 |
30 | 15678271 | Comparative tissue factor pathway inhibitor release potential of heparins. | 2005 Jan | 8 |
31 | 15876997 | Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. | 2005 Mar | 2 |
32 | 15351861 | Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. | 2004 Sep | 1 |
33 | 15570242 | Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. | 2004 Nov | 8 |
34 | 15815881 | Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor. | 2004 Dec | 1 |
35 | 12519315 | Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria. | 2003 Jan | 6 |
36 | 12624625 | Local tissue factor pathway inhibitor release in the human forearm. | 2003 Mar | 3 |
37 | 12801846 | Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells. | 2003 Jun | 5 |
38 | 12808176 | Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. | 2003 Jul | 10 |
39 | 12856386 | Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. | 2003 Jul | 2 |
40 | 12893029 | Tissue factor pathway inhibitor production by human proximal tubular epithelial cells in culture. | 2003 May 1 | 3 |
41 | 14574072 | Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor. | 2003 Feb | 2 |
42 | 14675115 | Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days. | 2003 Dec | 1 |
43 | 11772005 | Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. | 2002 Jan 8 | 4 |
44 | 11804978 | Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. | 2002 Jan 22 | 1 |
45 | 11848461 | Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein. | 2002 Jan | 1 |
46 | 11854880 | Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass. | 2002 Feb | 4 |
47 | 12021535 | Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients. | 2002 May | 1 |
48 | 12028043 | Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. | 2002 Jun | 1 |
49 | 12063117 | Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI). | 2002 Jun 18 | 4 |
50 | 12482841 | Characterization of the association of tissue factor pathway inhibitor with human placenta. | 2002 Dec 1 | 3 |